How do you approach a patient with metastatic urothelial carcinoma who has progressed on maintenance avelumab?
Assuming no actionable mutations?
Answer from: Medical Oncologist at Academic Institution
This patient would be in the 3rd line so options include Enfortumab vedotin (based on EV-201, cohort 1, published data, and EV-301 press release) or Erdafitinib (if FGFR2 or FGFR3 activating mutation or fusion based on BLC2001 trial published data) or clinical trial. Outside the US, without access t...
Comments
Medical Oncologist at Veterans Administration Health Care Center I think Dr. @Petros Grivas makes good points, but ...
I think Dr. @Petros Grivas makes good points, but ...